Skip to main content

Table 1 Characteristics of included studies

From: Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis

Study

(Author, Year)

Patient source

Type of study

Study period

Male

Median follow up (Months)

Number of patients

(RT + Sur/Sur)

Age (years)

Histological subtypes

RT + Sur

(%)

Sur

(%)

RT + Sur

Sur

RT + Sur

(%)

Sur

(%)

Chouliaras et al. 2019 [15]a

USA

RCS

2000–2016

37.0

37.0

31.4c

46/46

59.3 (50.5–68.5)d

64.6 (51.9–78.9)d

LPS (26.1)

LMS (34.8)

UPS (21.7)

Other (17.4)

LPS (30.4)

LMS (26.1)

UPS (28.2)

Other (15.3)

Turner et al. 2019 [12]

Canada

RCS

1990–2014

42.5

38.7

90.0c

40/62

56.7b

60.0b

LPS (32.5)

Other (72.6)

LPS (27.4)

Other (67.5)

Ecker et al

2016 [17]a

USA

RCS

2004–2013

54.6

55.5

52.0 (30.9–75.1)d

174/173

\(\le\) 63 (57.7%)

64.0–72 (25.3%)

\(\ge\) 72 (17.2%)

\(\le\) 63 (52.0%)

64–72 (28.3%)

\(\ge\) 72 (19.7%)

NR

NR

Kelly et al

2015 [16]

USA

RCS

2003–2011

47

51

Treat 36.9c

Control 38.8c

32/172

57.0 (41.0–85.0)c

62.0 (26.0–92.0)c

LPS (59.4)

LMS (25.0)

MPNST (3.1)

Other (12.5)

LPS (68.0)

LMS (28.5)

MPNST (1.7)

Other (1.8)

Nussbaum et al

2016 [18]a

USA

RCS

2003–2011

56.0

54.0

Treat

42.0 (27.0–70.0)d

Control

43.0 (25.0–64.0)d

563/1126

59.2 (13.8)b

59.5 (14,5)b

LPS (37.4)

LMS (27.2)

MFH (8.0)

MPNST (1.7)

Other (25.7)

LPS (40.9)

LMS (27.6)

MFH (6.7)

MPNST (0.7)

Other (24.1)

Lane et al. 2015 [22]

USA

RCS

1990–2011

37.5

41.7

Treat

84.4 (58.6–94.3)d

Control

25.0 (4.2–52.5)d

8/12

52.5 (47.0–62.2)d

48.5 (43.2–60.5)d

LPS (87.5)

LMS (12.5)

UPS (0.0)

Other (0.0)

LPS (41.6)

LMS (41.7)

UPS (0.0)

Other (16.7)

Bonvalot et al. 2020 [11]a

Europe

USA

Canada

RCT

2012–2017

53.0

50.0

43.1 (28.8–59.2)d

133/133

61.0 (52.0–68.0)d

61.0 (53.0–67.0)d

LPS (73.6)

LMS (12.0)

Other (14.4)

LPS (75.2)

LMS (16.5)

Other (8.3)

Ma et al. 2020 [19]a

USA

RCS

2006–2015

55.3

55.2

48.7 (27.6–76.8)d

844/844

\(<\) 65 (55.7%)

\(\ge\) 65 (44.3%)

\(<\) 65 (56.5%)

\(\ge\) 65 (43.5%)

LPS (47.1)

LMS (27.3)

MFH (2.7)

MPNST (1.5)

Other (21.4)

LPS (45.6)

LMS (26.5)

MFH (2.1)

MPNST (1.9)

Other (23.9)

Bremjit et al. 2014 [14]

USA

RCS

2000–2013

41.7

31.8 (1.4–257.3)c

40/92

54.8 (25.8–88.5)c

LPS (60.6)

LMS (22.0)

Other (17.4)

Snow et al. 2018 [20]

Australia

RCS

2008–2016

61.0

NR

62/32

59.0 (18.0–86.0)c

LPS (53.2)

LMS (18.1)

UPS (7.4)

Other (21.3)

Bonvalot et al. 2009 [13]

France

RCS

1985–2005

51.8

52.8 (12.0–216.0)c

122/260

57.0 (14.0–87.0)c

LPS (49.7)

LMS (17.8)

MFH (8,9)

Other (23.6)

Berger et al. 2018 [21]

USA

RCS

2004–2013

47.6

NR

272/2490

62.9 (11.2)b

NR

Study

(Author, Year)

Tumour size (cm)

Surgical margins

Radiotherapy

Dose (Gy)

Other radiotherapy

Chemotherapy

(Y/N)

Outcome

HR (95%CI)

NOS score

RT + Sur

Sur

Treat

(Neg/Tol)

Control

(Neg/Tol)

Chouliaras et al. 2019 [15]a

13.75 (9.5–19.0)d

15.25 (10.2–21.0)d

26/46

23/46

NR

NR

Y

(Treat: 32.6%; Control: 10.9%)

OS

1.14 (0.60–2.17)

8

RFS

0.98 (0.52–1.84)

LR

1.18 (0.51–2.74)

Turner et al. 2019 [12]

136.5c

184.0c

29/40

19/62

49.0c

NR

N

OS

0.42 (0.19–0.90)

8

RFS

0.43 (0.24–0.79)

Ecker et al. 2016 [17]a

\(\le\) 10 (13.2%)

10–20 (42.0%)

\(\ge\) 20 (44.8%)

\(\le\) 10 (10.4%)

10–20 (45.7%)

\(\ge\) 20 (43.9%)

NR

NR

50.0 (45.0–50.4)c

NR

Y

(Treat: 13.2%; Control: 11.0%)

OS

0.64 (0.42–0.99)

8

Kelly et al. 2015 [16]

 < 18 (63.0%)

\(\ge\) 18 (38.0%)

 < 18 (48.0%)

\(\ge\) 18 (52.0%)

14/32

105/172

50.4 (14.0–62.0)c

IOERT

(Treat: 47.0%)

N

DSS

0.52 (0.12–2.22)

8

Nussbaum et al. 2016 [18]a

15.4 (11.9)b

16.0 (11.9)b

NR

NR

NR

NR

N

OS

0.70 (0.58–0.84)

8

Lane et al. 2015 [22]

\(<\) 5 (0%)

5–10 (62.5%)

10–15 (25.0%)

\(>\) 15 (12.5%)

\(<\) 5 (27.3%)

5–10 (9.1%)

10–15 (9.1%)

\(>\) 15 (54.5%)

3/8

4/12

45.0 (32.4–56.2)c

IOETR

(Treat:

75.0%)

Y

(Treat: 12.5%; Control: 41.7%)

OS

0.30 (0.11–0.82)

8

RFS

0.34 (0.17–0.69)

Bonvalot et al. 2020 [11]a

16.0 (11.1–21.0)d

16.7 (12.4–21.0)d

114/119

122/128

50.4

NR

N

RFS

1.01 (0.71–1.44)

8

Ma et al. 2020 [19]a

NR

NR

568/844

552/844

NR

NR

N

OS

0.88 (0.77–0.99)

8

Bremjit et al. 2014 [14]

18.5 (3.0–55.0)c

Neg/Tol: 60/66

NR

NR

Y

(21.2%)

OS

0.70 (0.30–1.60)

7

Snow et al. 2018 [20]

130.0 (20.0–420.0)c

130.0 (76.7–190.0)d

Neg/Tol: 83/94

NR

NR

N

OS

1.00 (0.40–2.70)

7

RFS

0.33 (0.13–0.84)

Bonvalot et al. 2009 [13]

18.0 (3.0–60.0)c

Neg/Tol:176/382

45.0(10.0–66.0)c

IOETR

(4.7%)

Dose

(10–18)

Y

(38.0%)

LR

0.64 (0.45–0.90)

7

Berger et al. 2018 [21]

19.9 (11.9)b

Neg/Tol:1445/2762

NR

post-RT

(19.9%)

N

OS

0.89 (0.69–1.14)

7

  1. CI confidence interval, DSS disease-specific survival, HR hazard ratio, IOERT intraoperative radiation therapy, MFH malignant fibrous histiocytoma, MPNSTL malignant peripheral nerve sheath tumor, LMS leiomyosarcoma, LPS liposarcoma, LR local recurrence, Neg negative, N no, NR not reported, OS overall survival, Pos positive, RCS retrospective cohort study, RCT randomized clinical trial, RFS recurrence-free survival, RT radiotherapy, Sur surgery, Tol total, UPS undifferentiated pleomorphic sarcoma, Y yes
  2. LR is defined as a new tumor lesion detected near the primary lesion after surgical resection
  3. aPropensity score matched (PSM)
  4. bData are mean or mean (SD)
  5. cData are median or median (range)
  6. dData are median (IQR)
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us